ANAPTYSBIO, INC (ANAB)
AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
Address
10770 WATERIDGE CIRCLE, SUITE 210
SAN DIEGO, CA 92121
Founded
2005
Number of Employees
117
Website
http://www.anaptysbio.com
Buyback
| Buyback Data | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $ Amount Purchased ($ in 000s) |
- | - | - | - | - | - | - | - | - | $50,005 | - | $50,005 |
| Average Price | - | - | - | - | - | - | - | - | - | $23.54 | - | $23.54 |
| # Shares Purchased | - | - | - | - | - | - | - | - | - | 2,124,214 | - | 2,124,214 |
| Buyback Performance | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Return to Date | - | - | - | - | - | - | - | - | - | 69.9% | - | 69.9% |
| S&P 500 Return to Date | - | - | - | - | - | - | - | - | - | 31.3% | - | 31.3% |
| Excess Total Return | - | - | - | - | - | - | - | - | - | 38.6% | - | 38.6% |
| Quartile Rank |
|
|
|
|
|
|
|
|
|
|
|
|
| Percentile Rank | - | - | - | - | - | - | - | - | - | 92% | - | 78% |
Buyback returns calculated using weighted average buyback price over the last 10 years and comparing to current day stock price value. S&P 500 used as benchmark for excess return.
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)
Never miss an email alert when insiders at ANAB make a trade.
Creating a free account takes less than one minute